Stryker increases share repurchase program by $3 billion
Stryker Corporation released its third quarter 2026 results on October 29, 2026. The company also announced that its board of directors approved a $3 billion increase to its existing share repurchase program, in addition to the $1.0 billion spent on repurchases during the third quarter.
Key points
- The company reported its financial results for the third quarter of 2026 on October 29, 2026.
- To evaluate performance and analyze future trends, Stryker uses non-GAAP measures, or data that does not follow generally accepted accounting principles.
- The company recorded expenses tied to European Union medical regulatory requirements, including quality system updates, product labeling, and asset write-offs.
Operating results and corporate changes
The company reported its financial results for the third quarter of 2026 on October 29, 2026. Stryker repurchased $1.0 billion of its own shares during that quarter. In October 2026, the board of directors approved expanding the share repurchase program by increasing its limit by $3 billion.
Stryker changed its organizational structure in the first quarter of 2026. The company combined its Orthopaedic Instruments and Other Orthopaedics divisions into a new business unit called Ortho Tech, while Neuro Cranial and Enabling Technologies were integrated into the Instruments structure. All historical financial figures were restated to reflect these changes.
2026 share repurchase activity
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Use of adjusted financial metrics
To evaluate performance and analyze future trends, Stryker uses non-GAAP measures, or data that does not follow generally accepted accounting principles. Company management uses these for budget planning, analyzing business segments, and determining portions of management compensation.
Expenses and risks
The company recorded expenses tied to European Union medical regulatory requirements, including quality system updates, product labeling, and asset write-offs. Expenses for resolving product recalls and lawsuits, based on estimates of probable losses, were also included.
Stryker faces risks including cyber incidents, product quality requirements, and legislative changes. Because non-GAAP measures are not standardized, the company notes they may be difficult to compare with similar metrics from other organizations.
What to watch
Investors should monitor future company reports to track the pace of the $3 billion share repurchase limit utilization.
Leadership changes are also a significant event for the company. Effective January 1, 2027, current president and chief operating officer Spencer Stiles will become chief executive officer, and Kevin Lobo will move to the role of executive chair of the board of directors.
Original sources
- 8-K filing, October 29, 2026
- 8-K EX-99.1 filing, October 29, 2026
- 8-K filing, October 6, 2026
- 8-K EX-99.1 filing, October 6, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Stryker
A notification in your browser or on your phone when we publish about Stryker. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
